Stocks / ABT / P/E Ratio

Abbott Laboratories P/E Ratio 2007–2025

Abbott Laboratories reported 33.07 of price-to-earnings ratio for fiscal 2025. That was 131.8% higher than fiscal 2024. Compared with fiscal 2020, the change was -15.8%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.

Latest filed value
33.07
One-year change
+131.8%
Change since 2020
-15.8%
Latest period end
2025-12-31
Abbott Laboratories P/E Ratio history from 2007 to 2025FY 2007: 15.857467300289752FY 2008: 11.44823776377625FY 2009: 10.123004283113218FY 2010: 11.576374657237015FY 2011: 13.862997355379898FY 2012: 13.493312374270793FY 2013: 18.428388053988233FY 2014: 24.06023524751599FY 2015: 12.5071159780842FY 2016: 34.065096429053774FY 2017: 180.30086093478732FY 2018: 47.23976536800986FY 2019: 37.2337970918822FY 2020: 39.28373718261719FY 2021: 32.535793091439956FY 2022: 26.004777601003035FY 2023: 31.894861701076017FY 2024: 14.264563116103567FY 2025: 33.06560516357422
Annual filed history. Hover chart points for raw values; the accessible table below is the source of record.
Fiscal yearP/E RatioChange (YoY)
FY 202533.07+131.8%
FY 202414.26-55.3%
FY 202331.89+22.7%
FY 202226.00-20.1%
FY 202132.54-17.2%
FY 202039.28+5.5%
FY 201937.23-21.2%
FY 201847.24-73.8%
FY 2017180.30+429.3%
FY 201634.07+172.4%
FY 201512.51-48.0%
FY 201424.06+30.6%
FY 201318.43+36.6%
FY 201213.49-2.7%
FY 201113.86+19.8%
FY 201011.58+14.4%
FY 200910.12-11.6%
FY 200811.45-27.8%
FY 200715.86

Source: Abbott Laboratories SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open ABT 10-K filings at SEC EDGAR · Methodology · Download CSV.

How to read this history

Abbott Laboratories reported 33.07 of price-to-earnings ratio for fiscal 2025. That was 131.8% higher than fiscal 2024. Compared with fiscal 2020, the change was -15.8%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.

Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.

See the full picture for Abbott Laboratories

Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.

Open the interactive view — free

Abbott Laboratories — frequently asked questions

What is Abbott Laboratories's price-to-earnings ratio?

Abbott Laboratories (ABT) reported price-to-earnings ratio of 33.07 for fiscal year 2025, per its SEC filings.

How has Abbott Laboratories's price-to-earnings ratio changed over time?

Between fiscal 2007 and 2025, ABT's price-to-earnings ratio grew at roughly 4.2% per year (compound annual rate), from 15.86 to 33.07.

Where does this data come from?

Figures are computed from Abbott Laboratories's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.

More ABT financial history

Full ABT fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →